MEDTRONICMM

MEDTRONIC

82.18EURD
−0.62−0.75%
Last update at Mar 26, 16:45 GMT
EUR
No trades
See on Supercharts

4MDT fundamentals

Key facts

Market capitalization‪111.86 B‬EUR
Founded2014
Employees (FY)‪95 K‬
CEOGeoffrey Straub Martha
About

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Ownership
‪‪1.28 B‬‬
Free Float shares
‪‪1.28 B‬‬ (99.88%)
Closely held shares
‪‪1.59 M‬‬ (0.12%)
Free Float shares
‪‪1.28 B‬‬ (99.88%)
Closely held shares
‪‪1.59 M‬‬ (0.12%)
Capital structure
Market cap
‪‪111.86 B‬‬
Debt
‪‪25.69 B‬‬
Minority interest
‪‪220.13 M‬‬
Cash & equivalents
‪‪7.65 B‬‬
Enterprise value
‪‪130.12 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪111.86 B‬‬
Price to earning ratio (P/E)
28.59x
Price to sales ratio (P/S)
3.64x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
28.59x
Price to sales ratio (P/S)
3.64x
Valuation ratios
‪0.00‬
‪0.90‬
‪1.80‬
‪2.70‬
‪3.60‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪7.5%‬
‪10.0%‬
‪12.5%‬
‪15.0%‬
‪17.5%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Cardiovascular
Neuroscience
Medical Surgical
Diabetes
Other
By country
Period: 2023
United States
Non-United States Developed Markets
Emerging Markets
Ireland

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬
Actual
Estimate
Earnings
Next:May 21, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
84.80%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
2.97%
Last payment
0.672
Last ex-date
Dec 27, 2024
Dividend history
‪1.5%‬
‪2.0%‬
‪2.5%‬
‪3.0%‬
‪3.5%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪7.00 B‬‬
‪‪14.00 B‬‬
‪‪21.00 B‬‬
‪‪28.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪17.00 B‬‬
‪‪34.00 B‬‬
‪‪51.00 B‬‬
‪‪68.00 B‬‬
Assets
Liabilities